Zim Laboratories Limited has informed the Exchange about Investor Presentation

ZIM LABORATORIES LIMITED __________________________________________________________________________________________ www.zimlab.in I info@zimlab.in I CIN : L99999MH1984PLC032172 Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square, Maharashtra, India. Ph. + 91.718.271370 I Fax : +091.7118.271470 Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960 Ref No.: ZLL/CS/BM/BSE-NSE Date : 20.05.2025 BSE Limited, Market Operations Dept. P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400 National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB) Dear Sir, Sub : Q4 & FY25 Earnings Presentation Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed Q4 & FY25 - Earnings Presentation. Kindly take the intimation on record. Thanking you, Yours faithfully, For ZIM LABORATORIES LIMITED (Piyush Nikhade) Company Secretary and Compliance Officer Membership No. A38972 Encl : As above. PIYUSH SIDDHESHWAR NIKHADEDigitally signed by PIYUSH SIDDHESHWAR NIKHADE DN: c=IN, postalCode=440012, st=MAHARASHTRA, street=325 MAHALAXMI APPT NAGPURDHANTOLIWEST CENTREL ROAD 440012, l=NAGPUR, o=Personal, title=3526, serialNumber=3cced6ca26d23668ee558b723602e5236d527adc99269a3746951cdb919fca04, pseudonym=352620221206180703459, 2.5.4.20=42e9b6a98356f9095ec25716fc30d8cb8463fc1dc23adada5293c43849baaf78, email=CSPIYUSHNIKHADE@GMAIL.COM, cn=PIYUSH SIDDHESHWAR NIKHADE Date: 2025.05.20 18:07:49 +05'30' Adobe Acrobat version: 11.0.17Q4 & FY25 –EARNINGS PRESENTATIONZIM LABORATORIES LIMITEDSAFE HARBOURThepresentationhasbeenpreparedbyZIMLaboratoriesLimited(“ZIM”orthe“Company”)solelyforinformationpurposesanddoesnotconstituteanoffertosellorrecommendationorsolicitationofanoffertosubscribefororpurchaseanysecuritiesandnothingcontainedhereinshallformthebasisofanycontractorcommitmentwhatsoever.Byaccessingthispresentation,youareagreeingtobeboundbythetradingrestrictions.Theinformationcontainedinthispresentationshouldbeconsideredinthecontextofthecircumstancesprevailingatthetimeandhasnotbeen,andwillnotbe,updatedtoreflectmaterialdevelopmentswhichmayoccurafterthedateofthepresentation.Theinformationsetouthereinmaybesubjecttoupdating,completion,revision,verificationandamendmentandsuchinformationmaychangematerially.Thispresentationisbasedontheeconomic,regulatory,marketandotherconditionsasineffectonthedatehereof.Itshouldbeunderstoodthatsubsequentdevelopmentsmayaffecttheinformationcontainedinthispresentation,whichneithertheCompanynoritsaffiliates,advisorsorrepresentativesareunderanobligationtoupdate,reviseoraffirm.CertainstatementscontainedinthispresentationmaybestatementsoftheCompany’sbeliefs,plansandexpectationsaboutthefutureandotherforward-lookingstatements.Theforward-lookingstatementsarebasedonmanagement’scurrentexpectationsorbeliefsaswellasanumberofassumptionsabouttheCompany’soperationsandfactobeyondtheCompany’scontrolorthird-partysourcesandinvolveknownandunknownrisksanduncertaintiesthatcouldcauseactualresultstodiffermateriallyfromthosecontemplatedbytherelevantforward-lookingstatements.Forwardlookingstatementscontainedinthispresentationregardingpasttrendsoractivitiesshouldnotbetakenasarepresentationthatsuchtrendsoractivitieswillcontinueinthefuture.Thereisnoobligationtoupdateorreviseanyforward-lookingstatements,whetherasaresultofnewinformation,futureeventsorotherwise.Youshouldnotplaceunduerelianceonforwardlookingstatements,whichspeakonlyasofthedateofthispresentation.TheCompany,assuch,makesnorepresentationorwarranty,expressorimplied,asto,anddoesnotacceptanyresponsibilityorliabilitywithrespectto,thefairness,accuracy,completenessorcorrectnessofanyinformationoropinionscontainedherein.YouacknowledgeandagreethattheCompanyand/oritsaffiliatedcompaniesand/ortheirrespectiveemployeesand/oragentshavenoresponsibilityorliability(expressorimplied)whatsoeverandhowsoeverarising(including,withoutlimitationforanyclaim,proceedings,action,suits,losses,expenses,damagesorcosts)whichmaybebroughtagainstorsufferedbyanypersonasaresultofactinginrelianceuponthewholeoranypartofthecontentsofthispresentationandneithertheCompany,itsaffiliatedcompaniesnortheirrespectiveemployeesoragentsacceptsanyliabilityforanyerror,omissionormisstatement,negligentorotherwise,inthispresentationandanyliabilityinrespectofthepresentationoranyinaccuracythereinoromissiontherefromwhichmightotherwiseariseisherebyexpresslydisclaimed.2CONTENT301EXECUTIVE SUMMARY –FY2502FINANCIAL HIGHLIGHTS03BUSINESS MIX04R&D & INNOVATION05SHAREHOLDINGBusiness PerformanceoTotal Operating Income grew to ₹3,790 Mn (↑3.2% YoY), driven by sustained export momentum and high-value innovative product contributionsoExport revenue stood at ₹3,125 Mn (↑8.9% YoY), contributing 82% to the TOIoEBITDA increased to ₹495 Mn, with margin improving to 13.1% (vs. 12.7% in FY24)oPAT declined to ₹122 Mn due to increased finance and depreciation costsGrowth in NIP + OTFoRevenue from our New Innovative Products (NIP) rose by 81.8% YoY to ₹437 MnoRevenue from Oral Thin Films grew 41.8% YoY to ₹186 MnoCombined revenue from NIP, OTF, and licensing grew to ₹722 Mn from ₹438 Mn (19% up) Momentum in Business Development EXECUTIVE SUMMARY –FY25Progress in Regulatory Filings and Approvalso12 NIP products in pipeline; 7 filed in the EU, others across Pharmerging and RoWo5 NIP + 6 OTF dossiers filed in EU during the yearoSecured 2 EU Marketing Authorizations for Dimethyl Fumarate (NIP) and Azithromycin Oral Suspension; MA in Buprenorphine OTF obtained by partner for EUoExpanded presence through ZIMTAS (Australia) and new Scientific Office in UAE to support regional filings and commercializationoLandmark agreement with UAE partner for technology out licensing in OTF for local marketoExperienced professionals being onboarded to support BD in specific regions Investment in Infrastructure and R&Do₹365 Mn invested in Capex –including Urology Suite and Specialized Nutra SuiteoR&D investment of ₹103 Mn focused on BE studies, regulatory filings, and innovation scale-up.oEU GMP and NSF ANSI 455 -2 re-audit successfully completedoMaintained gearing at 44% despite higher borrowings to support expansions45EBITDA at ₹163 Mn, up 22% from Q3; EBITDA margins improved to 15% , up from 13.8% in Q3FY25Q4 FY25₹65 Mn was added to Gross Block with investments in business expansion and registrationsTotal Operating Income at ₹3,790 Mn, reflecting an 3.2% YoY growth from ₹3,674 Mn in FY24EBITDA is at ₹495 Mn, up 6.4% YoY from ₹465 Mn in FY24; margins improved to 13.1% from 12.7%₹365 Mn invested in Capex including ₹103 Mn towards BE studies and regulatory filingsTotal R&D spend was at ₹333 Mn, accounting for 8.8% of the Total Operating IncomeTotal Operating Income at ₹1,087 Mn, reflecting a 12.9% QoQ growth R&D spend at ₹76 Mn (7% of TOI), driven by BE studies and registrationsFINANCIAL HIGHLIGHTS3,790 Mn13.1%365 Mn8.8%1,087 Mn15%65 Mn7%STRATEGIC & EXECUTION UPDATES6Innovative Products (NIP + OTF)oWe successfully completed two key CapEx projects in FY25—the Urology NIP Suite and the Liquid in Pellet technology Suite—strengthening our manufacturing capabilities for high-value innovative productsoWe invested ₹365 Mn in FY25 to complete ongoing Capex projects and optimize plant operations including ₹103Mn towards BE studies and filingsoNIP and OTF operating income reached ₹624 Mn in FY25, marking a 68% YoY growthoThis growth was accompanied by key agreements, resulting in dossier licensing and milestone fees totaling ₹98 Mn during the yearoNIP + OTF contribution to total operating income was 19% in FY25Product Filings & DevelopmentoIn FY25, we completed 23 NIP (6 molecules), 17 OTF (5 molecules), and 10 FF (5 molecules) filings, including 5 NIP (4 molecules) and 6 OTF (2 molecules) filings in the EU, and 1 NIP and 1 OTF filing in Australia via our Australian subsidiary.oWe received 3 EU MAs in FY25 -2 for NIP (Azithromycin & Dimethyl Fumarate) and 1 for OTF (Buprenorphine) via our partner, Neuraxpharm across EUCapex & Project ProgressBusiness Development & MarketingoCollaborated with Globalpharma Co. L.L.P. to commercialize Oral Thin Film products in the GCC region and strengthen Middle East presenceoScientific Office (Middle East) and Australian subsidiary (ZIMTAS Pty. Ltd.) established; regulatory filings for innovative products underwayoRegional teams and experienced BD leads appointed to accelerate growth across MENA, Australia, and other key marketsNIP + OTF mix: 19% of TOI23 NIP FILINGS₹365 Mn CAPEXSPECIFIC REGION WISE BD STRATEGYFINANCIAL PERFORMANCE –FY2573,6743,790FY24FY25Total Operating Income (₹ Mn)Total Operating Income465495FY24FY25EBITDA (₹ Mn)EBITDA & EBITDA margin12.7%12.7%13.1%13.1%4.7%4.7%3.2%3.2%Profit After Tax (PAT) & PAT marginoTotal Operating Income grew 3.2% YoY, driven by contributions from our Innovative Product basket (NIP + OTF) ; we faced headwinds such as political instability and currency issues resurging in some of our core markets resulting in under performance compared to our guidanceoEBITDA grew 6.4% YoY on account of improved product mix oPAT reduction was due to higher interest costs (₹ 114 Mn vs. ₹ 69 Mn in FY24) and depreciation costs (₹ 201 Mn vs. ₹ 160 Mn in FY24)172122FY24FY25PAT (₹ Mn)229315FY24FY25Interest + Depreciation CostsInterest + DepreciationFINANCIAL PERFORMANCE –Q4FY2581,1799631,087Q4FY24Q3FY25Q4FY25Total Operating Income (₹ Mn)Total Operating Income172133163Q4FY24Q3FY25Q4FY25EBITDA (₹ Mn)EBITDA & EBITDA margin14.6 %14.6 %13.8 %13.8 %6.9 %6.9 %4.2 %4.2 %Profit After Tax (PAT) & PAT marginoTotal Operating Income stood at ₹ 1,087, reflecting a 12.9% QoQ growthoEBITDA was at ₹163 Mn and margin was at 15% and grew 22.6% QoQ from ₹133 MnoPAT was at ₹49 Mn with margin at 4.5% and grew 22.1% QoQ from ₹40 Mn814049Q4FY24Q3FY25Q4FY25PAT (₹ Mn)15%15%4.5%4.5%BUSINESS MIX9oFY25: The Pharma business contributed 75% of revenue, totalling ₹2,836 Mn, while the Nutra business accounted for 25% at ₹954MnoQ4 FY25: The Pharma business contributed 82% of revenue while the Nutra business accounted for 18% of revenue. The mix of business tends to change based on the impact from specific marketsPharma Revenue (₹Mn) & Contribution to Total Operating Income (%)Nutra Revenue (₹Mn) & Contribution to Total Operating Income (%)25520126626822419626%17%33%29%23%18%Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY2570897855265473989174%83%67%71%77%82%Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25REVENUE MIX102,870, 78%646, 18%158, 4%FY243,125, 83%536, 14%130, 3%FY25969, 82%185, 16%25, 2%Q4FY24878, 81%178, 16%32, 3%Q4FY25Export India Deemed ExportoFY25: Revenue from exports increased 8.9% YoY to ₹3,125 Mn, compared to ₹2,870 Mn in FY24 oGrowth in Exports was supported by new marketing partnerships and increased sales of innovative products, while the shift away from lower-margin deemed exports aligns with the focus on higher-value productsoQ4 FY25: Revenue from export business reduced YoY in absolute terms but contributed similarly towards the business mixNumbers in ₹MnINNOVATIVE PRODUCT CONTRIBUTION11701098211217816413514710.3%12.7%8.5%9.5%21.8%17.8%14.0%13.5%Q1FY24Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25(NIP + OTF) Revenue (₹Mn) & Contribution to Total Operating Income (%)oFY25: NIP + OTF operating income contribution grew 68% YoY to ₹624 Mn for FY25, up from ₹372 Mn in FY24; NIP was ₹437 Mn & OTF was.₹186 Mn for FY25; contribution to total operating income was 19% including licensing feesoAgreements for Innovative Products across regions resulted in ₹98 Mn from dossier licensing milestone payments vs ₹66 Mn in FY24oQ4FY25: NIP + OTF operating income contribution grew 31.5% YoY to ₹147 Mn, up from ₹112 Mn in Q4FY24₹624 Mn in FY25; Up 68% YoY₹372 Mn, in FY24Commercial SuppliesRegulatory ApprovalsRegulatory FilingBE StudiesValidationFormulationDevelopmentMarket ReviewTherapyAreaProductUrology Product1GastrointestinalProduct2Anti –CoagulantProduct3CNSDi-MethylFumarateUrologyProduct5Rheumatoid ArthritisProduct6Anti-InfectiveAzithromycinSuspensionAnalgesicProduct8GastrointestinalProduct9GastrointestinalProduct10Skin Disorders (Anti psoriatic)Product11UrologyProduct1212ADVANCING INNOVATION : NIP PRODUCT PIPELINE (EU/UK)Commercial SuppliesRegulatory ApprovalsRegulatory FilingBE StudiesValidationFormulationDevelopmentMarket ReviewTherapyAreaProductCNSRizatriptanErectile DysfunctionSildenafilCNSProduct3Erectile DysfunctionProduct4Opioid De AddictionBuprenorphine13ADVANCING INNOVATION : OTF PRODUCT PIPELINE (EU/UK)R&D DRIVING PRODUCT INNOVATION1455%65%16%4%29%31%FY24FY25Capital Expenses on BE study,registrations etcCapital Expenses onInfrastructure & EquipmentR&D Expenses in P&L(Employee; Material,BE-Studyetc.)8.8%9.7%9090227676R&D TeamSizeR&D TeamSizePhDsPhDsPost-GraduatesPost-GraduatesR&D Expense Mix % of Total R&D Investment and Total R&D Investment as % of Total Operating Income 7744₹333 Mn₹333 MnNIP Filed in the EU to dateNIP Filed in the EU to dateVersatile Technology PlatformsVersatile Technology PlatformsAllocated in FY25 on Opex, Facility, BE Studies, Registrations, etc.Allocated in FY25 on Opex, Facility, BE Studies, Registrations, etc.oFY25:₹103MnallocatedforBEstudiesandregistrations,advancingtheInnovativeProducts(NIP+OTF)pipelineoProgressinNIPdevelopmentandfilings,with7productsdevelopedandfiledinEUwhiletheremaining5plannedforfilinginFY26oQ4FY25:TotalR&Dallocationof₹76Mnfocusedonproductdevelopment,dossierupgrades,registrationsandinfrastructureINCOME STATEMENT15YoY%FY24FY25QoQ% Q3FY25 YoY%Q4FY24Q4FY25Particulars (₹ Mn)3.2%3,6743,79012.9%963(7.7%)1,1791,087Total Operating Income13%5258(5.6%)1810.7%1517Other Income3.3%3,7253,84812.6%981(7.5%)1.1941,104Total Income6.4%46549522.5%133(5.2%)172163EBITDA40bps12.7%13.1%120bps13.8%40bps14.6%15%EBITDA %(65.2%)69114(7.4%)27(26.1%)2329Finance Cost-160201(8.2%)48-3953Depreciation(23.8%)23618042.1%57(26.3%)11081Profit Before Tax (PBT)(170bps)6.4%4.7%150bps5.9%(190bps)9.3%7.4%PBT %(29.3%)17212222.1%40(39.7%)8149Profit After Tax (PAT)(150bps)4.7%3.2%30bps4.2%(240bps)6.9%4.5%PAT %(29.4%)3.542.523.2%0.82(39.2%)1.66EPS (₹ / Share)*(not annualised)1.01 BALANCE SHEET16FY22FY23FY24FY25Particulars (₹ Mn)1,9202,2573,0893,453Gross Block –Tangible & Intangible Assets including WIP1,1741,3572,0312,347Net Block –Tangible & Intangible Assets including WIP12115016160Other Non-Current Assets2,1211,9092,2762,313Current Assets3,4163,4164,4684,720Total Assets 1,7572,0032,3872,522Net Worth5135961,0641,122Borrowings1158130131Other Non-Current Liabilities1,135759887945Current Liabilities3,4163,4164,4684,720Total Equities & LiabilitiesGross Current Assets (₹ Mn) & % of Total AssetsNet Worth (₹ Mn)Total Borrowing (₹ Mn) & Gearing %Gross & Net Fixed Assets (₹ Mn)5135961,0641,12229%30%45%44%FY22FY23FY24FY25Total BorrowingsGearing171,7572,0032,3872,522FY22FY23FY24FY25Net Worth1,9202,2573,0893,4531,1741,3572,0312,347FY22FY23FY24FY25Gross Fixed AssetsNet Fixed AssetsKEY FINANCIALS 62%56%51%49%FY22FY23FY24FY25SHAREHOLDING18Ownership % (March 2025)•Number of Shareholders in Q4FY25 accounted to 17.4K•Promoter shareholdingis freeofanyencumbranceTraded Volume (In K) BSE+NSEPercentagefiguresroundedoffto showwholenumbers33%12%8%42%5%PromoterHNIBody CorporatesOther Public ShareholdingNRI & Foreign Individuals13,08914,09326,59318,43511,31314,10405,00010,00015,00020,00025,00030,000Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25THANK YOUI N V E S T O R R E L A T I O N SZIM’s InvestorRelationsMr. Zain Daudzain.daud@zimlab.inM: +919022434631GoIndia Advisors –IR FirmMs. Priya Sen Ms. Deepika Sharma Ms. Sheetal Khanduja priya@goindiaadvisors.comdeepika@goindiaadvisors.com sheetal@goindiaadvisors.comM:+918334841047M:+918451029510M:+91 9769364166 ZIM LABORATORIES LIMITEDAddress:Sadoday Gyan (Ground Floor), Opposite NADT, Nelson Square, Nagpur, Maharashtra 440013www.zimlab.in+91 712 2981960